Last reviewed · How we verify
IMVAMUNE
IMVAMUNE, developed by Bavarian Nordic, is a marketed vaccine with a key composition patent expiring in 2028. Its primary strength lies in its established market presence and regulatory approval. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | IMVAMUNE |
|---|---|
| Also known as | IMVANEX, MVA-BN®, MVA-BN Smallpox vaccine, Modified Vaccinia Ankara Smallpox Vaccine, IMVANEX® |
| Sponsor | Bavarian Nordic |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- MVA Post-Event: Administration Timing and Boost Study (PHASE1, PHASE2)
- Smallpox Vaccine for Mpox Post-Exposure Prophylaxis: A Cluster RCT (PHASE4)
- High Dose IMVAMUNE® in Vaccinia-Naive Individuals (PHASE2)
- JYNNEOS Smallpox Vaccine in Adult Healthcare Personnel at Risk for Mpox in the Democratic Republic of the Congo (PHASE3)
- A Study Exploring the Use of Vaccine and Antigen Challenges for Immune Monitoring in Healthy Participants (EARLY_PHASE1)
- Imvamune Vaccine for the Treatment of Non-melanoma Skin Cancer (PHASE1, PHASE2)
- Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid IMVAMUNE® (1x10^8 TCID50) Administered Subcutaneously and a Lower Dose Liquid IMVAMUNE® (2x10^7 TCID50) Administered Intradermally (PHASE2)
- A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IMVAMUNE CI brief — competitive landscape report
- IMVAMUNE updates RSS · CI watch RSS
- Bavarian Nordic portfolio CI